Disease exacerbation is common in inflammatory bowel disease patients treated with immune checkpoint inhibitors for malignancy

BACKGROUND: Colitis is a known potential toxicity of immune checkpoint inhibitors (ICIs). Studies evaluating the risk of disease exacerbation following ICI treatment in patients with pre-existing inflammatory bowel disease (IBD) are limited. AIM: To assess the clinical characteristics of IBD patient...

Descripción completa

Detalles Bibliográficos
Autores principales: Rubin, Samuel J S, Balabanis, Tatiana, Gubatan, John, Habtezion, Aida
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Baishideng Publishing Group Inc 2022
Materias:
Retrospective Cohort Study
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8891792/
https://www.ncbi.nlm.nih.gov/pubmed/35317167
http://dx.doi.org/10.12998/wjcc.v10.i6.1787

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8891792/
https://www.ncbi.nlm.nih.gov/pubmed/35317167
http://dx.doi.org/10.12998/wjcc.v10.i6.1787

Ejemplares similares